Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7461543 | 1.00 | SLC6A3 (0.56) | SLC6A3 | |
| SCHEMBL7461522 | 1.00 | SLC6A3 (0.56) | SLC6A3 | |
| SCHEMBL20348865 | 0.86 | SLC6A3 (0.57) | SLC6A3 | |
| SCHEMBL8782692 | 0.86 | SLC6A3 (0.42) | SLC6A3 | |
| SCHEMBL9139368 | 0.86 | SLC6A3 (0.42) | SLC6A3 | |
| SCHEMBL8782687 | 0.86 | SLC6A3 (0.42) | SLC6A3 | |
| SCHEMBL8782696 | 0.86 | SLC6A3 (0.42) | SLC6A3 | |
| SCHEMBL9139365 | 0.86 | SLC6A3 (0.42) | SLC6A3 | |
| SCHEMBL5593759 | 0.85 | SLC6A3 (0.52) | SLC6A3 | |
| SCHEMBL3921318 | 0.85 | SLC6A3 (0.52) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007034270-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (-) TRANS-N-METHYL PAROXETINE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007034270-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (-) TRANS-N-METHYL PAROXETINE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2007-03-29 | — | — | WO | disclosed |
| US-20050203140-A1 | Process for the preparation of paroxetine substantially free of alkoxy impurities | ENTIRE INTEREST | 2005-09-15 | — | — | US | disclosed |
| US-6930186-B2 | Process for the preparation of paroxetine substantially free of alkoxy impurities | TEVA PHARMACETICAL INDUSTRIES LTD. (IL) | 2005-08-16 | — | — | US | disclosed |
| EP-1406624-A4 | PROCESS FOR THE PREPARATION OF PAROXETINE SUBSTANTIALLY FREE OF ALKOXY IMPURITIES | TEVA PHARMA (IL) | 2005-03-30 | — | — | EP | disclosed |
| EP-1366041-A4 | PREPARATION OF N-METHYLPAROXETINE AND RELATED INTERMEDIATE COMPOUNDS | TEVA PHARMA (IL) | 2004-12-22 | — | — | EP | disclosed |
| US-6777554-B2 | REACTING SESAMOL-TETRABUTYLAMMONIUM SALT WITH 4-(4-FLUOROPHENYL)-3-CHLOROMETHYL-N-METHYL-PIPERIDINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-17 | — | — | US | disclosed |
| EP-1406624-A2 | PROCESS FOR THE PREPARATION OF PAROXETINE SUBSTANTIALLY FREE OF ALKOXY IMPURITIES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-04-14 | — | — | EP | disclosed |
| EP-1366041-A1 | PREPARATION OF N-METHYLPAROXETINE AND RELATED INTERMEDIATE COMPOUNDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002100829-A9 | PROCESS FOR THE PREPARATION OF PAROXETINE SUBSTANTIALLY FREE OF ALKOXY IMPURITIES | TEVA PHARMA (IL) | 2003-09-25 | — | — | WO | disclosed |
| US-20020151567-A1 | Preparation of N-methylparoxetine and related intermediate compounds | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IR) | 2002-10-17 | — | — | US | disclosed |
| EP-1246821-A2 | PROCESS FOR THE PREPARATION OF PAROXETINE AND SYNTHETIC INTERMEDITATES THEREOF | SmithKline Beecham plc (GB) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002062790-A1 | PREPARATION OF N-METHYLPAROXETINE AND RELATED INTERMEDIATE COMPOUNDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-08-15 | — | — | WO | disclosed |
| WO-2001004113-A2 | PROCESS FOR THE PREPARATION OF PAROXETINE AND SYNTHETIC INTERMEDITATES THEREOF | SMITHKLINE BEECHAM PLC (GB) | 2001-01-18 | — | — | WO | disclosed |
| WO-2001004093-A2 | PROCESS FOR PRODUCING PAROXETINE DERIVATIVES BY MITSUNOBU REACTION | SMITHKLINE BEECHAM PLC (GB) | 2001-01-18 | — | — | WO | disclosed |
| EP-0266574-B1 | Piperidine compounds and their preparation and use | NOVO NORDISK AS (DK) | 1994-01-05 | — | — | EP | disclosed |
| US-5019582-A | Preventing Calcium Overload In Brain Cells | NOVO NORDISK A/S (DK) | 1991-05-28 | — | — | US | disclosed |
| US-4985446-A | CALCIUM OVERLOAD BLOCKERS IN BRAIN CELLS | A/S FERROSAN (DK) | 1991-01-15 | — | — | US | disclosed |
| US-4877799-A | Method of treating calcium overload in brain cells of mammals | A/S FERROSAN (DK) | 1989-10-31 | — | — | US | disclosed |
| EP-0266574-A2 | Piperidine compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203140-A1 | Process for the preparation of paroxetine substantially free of alkoxy impurities | CYP2C19, CYP3A4, CYP3A5 | SLC6A3 1107/4885 |
| US-20020151567-A1 | Preparation of N-methylparoxetine and related intermediate compounds | PNMT, INMT, SLC6A4 | SLC6A3 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.